June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Role of Fibroblast Growth Factor derivatives in corneal endothelial regeneration
Author Affiliations & Notes
  • David Eveleth
    Trefoil Therapeutics, Inc., San Diego, California, United States
  • Footnotes
    Commercial Relationships   David Eveleth Trefoil Therapeutics, Inc., Code E (Employment), Trefoil Therapeutics, Inc., Code I (Personal Financial Interest), Trefoil Therapeutics, Inc., Code O (Owner), Trefoil Therapeutics, Inc., Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2409. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Eveleth; Role of Fibroblast Growth Factor derivatives in corneal endothelial regeneration. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2409.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Fibroblast growth factors are key drivers of the growth and development of the cornea. A modified version of fibroblast growth factor 1 (TTHX1114) has been developed that can protect endothelial cells from death, stimulate proliferation in these normally quiescent cells, and drive regeneration. This drug causes endothelial cells to proliferate in both normal and dystrophic corneas. Clinical studies show that TTHX1114 accelerates visual recovery after ocular surgery. The regenerated endothelial cells are morphologically and phenotypically normal. TTHX1114 may have utility in the treatment of endothelial diseases and injury.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×